脂质体紫杉醇在中晚期肺鳞癌维持治疗中的疗效观察
DOI: 10.3971/j.issn.1000-8578.2018.17.1042
Keywords: 脂质体紫杉醇,维持治疗,肺鳞癌,Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer,Advances of FGF/FGFR Signaling Pathway in Targeted Therapy for Squamous Cell Lung Cancer,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors for Advanced Squamous Cell Lung Carcinoma Patients with Sensitive EGFR Mutations,A Prospectively Monocentric Phase Ⅱ Clinical Analysis on PGC Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Stage Ⅲ-ⅣA Nasopharyngeal Carcinoma Patients,Clinical Effects of Maintenance Therapy Combining Autologous DC/CIK and Erlotinib on Elderly Patients with Advanced Non-small Cell Lung Cancer,Survival Analysis of Capecitabine Maintenance Therapy in Elderly Patients with#br# Advanced Metastatic Colorectal Cancer,Efficacy and Safety of Weekly Liposome-paclitaxel Combined with Tegafur on Metastatic Gastric Cancer,Expression and Significance of NapsinA,TTF-1,CK5/6,CK7 and P63 in Biopsy Specimen by Bronchoscope of Non-small Cell Lung Cancer,Clinical Significance of Cyfra21-1 Analysis Combined with SELDI-TOF-MS Technology in Lung Squamous Carcinoma,Maintenance Therapy with Gefitinib for Elderly Patients in Advanced Adenocarcinoma of Lung,Clinical Observations of Maintenance Therapy with Hechanpian for Patients in Intermidiate and Advanced Non-small Cell Lung Cancer,Expression and Clinical Significance of Annexin-1 in Lung Squamous Carcinoma Tissues,RNA Interference-mediated Significant Enhancement of Apoptosis in Yunnan Gejiu Lung Squamous Carcinoma Cells(YTMLC) by siRNA Expression Vector Targeting Survivin Gene,The Expression and Clinical Significance of p53 and Prol iferating Cell Nuclear Antigen (PCNA) in Lung Squamous Cell Carcinoma
Abstract:
摘要 目的 探讨以脂质体紫杉醇进行维持治疗对中晚期肺鳞癌患者的临床疗效及安全性。方法 57例中晚期肺鳞癌患者完成4~6周期一线治疗后，被随机分为脂质体紫杉醇单药维持治疗组29例和随访观察组28例。观察治疗组患者的疗效及不良反应，比较两组无进展生存期（PFS）及总生存期（OS）。结果 脂质体紫杉醇单药维持治疗组的CR、PR、SD和PD分别为0、13.8%、44.8%和41.4%，疾病控制率（DCR）为58.6%，主要不良反应为骨髓抑制及胃肠道反应。两组患者中位PFS分别为5.7和2.4月，中位生存期（MST）分别为7.3和4.9月（均P<0.05），脂质体紫杉醇治疗组的生活质量（QOL）优于观察组。结论 脂质体紫杉醇作为中晚期肺鳞癌一线治疗后的维持治疗，可显著改善治疗组患者PFS及OS，改善生活质量，不良反应可以耐受
Full-Text
